• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

New Software Combines Pre-Op MRI Guidance with Live Ultrasound for Brachytherapy Treatment of Prostate Cancer

News
Article

The MIM Software HDR Prostate reportedly enables clinicians to utilize preoperative MRI guidance and live ultrasound imaging to enhance tumor visualization during high dose-rate (HDR) brachytherapy treatments for prostate cancer.

Offering an array of imaging-guided benefits for enhancing the precison of brachytherapy treatments for prostate cancer, GE HealthCare has launched MIM Symphony HDR Prostate software at the World Congress of Brachytherapy (July 10-13) in National Harbor, Md.

While computed tomography (CT) and ultrasound are commonly utilized in planning brachytherapy treatments, GE HealthCare said the combination of live ultrasound with preoperative magnetic resonance imaging (MRI) guidance can elevate the precision of high dose-rate (HDR) brachytherapy.

New Software Combines Pre-Op MRI Guidance with Live Ultrasound for Brachytherapy Treatment of Prostate Cancer

One of the benefits of the MIM Symphony HDR Prostate software is a ReSlicer feature that addresses differences between supine MRI views and ultrasound lithotomy procedures, according to GE HealthCare, the manufacturer of the software. (Image courtesy of GE HealthCare.)

Emphasizing the capability of MIM Symphony HDR Prostate to facilitate accurate alignment of MRI contours with live ultrasound, the company said key benefits of the software include:

• use of the ReSlicer tool to address differences between supine MRI views and ultrasound lithotomy procedures;

• optimized needle placement that can be utilized even with movement of the prostate during the procedure; and

• automated digitization of needles on planning images.

(Editor’s note: For additional related content on prostate cancer imaging, click here.)

“I often get the question, what is the best imaging modality for planning HDR prostate procedures, ultrasound or CT? My response is always MRI. MRI guidance enables more confident, precise treatments and reduces toxicity to organs at risk. I’ve had the pleasure of providing my patients with precise treatments using MRI guidance in MIM Symphony HDR Prostate, and I look forward to other clinics having the same opportunity,” noted Peter Rossi, M.D., FABS, a radiation oncologist at Valley View Hospital in Glenwood Springs, Colo., and chairman of the board for the American Brachytherapy Society.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Nina Kottler, MD, MS
Brian F. Chapin, MD
prostate cancer doctors
Related Content
© 2024 MJH Life Sciences

All rights reserved.